GlobalData on MSN4d
AstraZeneca’s Tagrisso gains FDA approval for stage III NSCLC
Tagrisso, which targets exon 19 deletions or exon 21 (L858R) mutations, received the approval following a priority review.
Zacks.com on MSN5d
AZN's Tagrisso Gets FDA Nod for Expanded Use in NSCLC
AstraZeneca AZN announced that the FDA has approved its blockbuster drug, Tagrisso (osimertinib) for expanded use in lung ...
FiercePharma5d
AstraZeneca’s Tagrisso follows up ASCO standing ovation with lung cancer FDA nod
In June, at the American Society of Clinical Oncology (ASCO) conference in Chicago, when AstraZeneca discussed results from a ...
Cure Today6d
FDA Approves Tagrisso for Some With Advanced NSCLC
Tagrisso has been approved for some adults with locally advanced, unresectable stage 3 non-small cell lung cancer.
AstraZeneca's Top-Selling Cancer Drug Tagrisso Receives FDA Green Light For Another Lung Cancer Indication
The FDA has approved AstraZeneca's Tagrisso for treating unresectable, Stage III EGFR-mutated non-small cell lung cancer, ...
AstraZeneca: FDA Approves Tagrisso To Treat Unresectable Stage III Lung Cancer
British drug major AstraZeneca PLC (AZN, AZN.L) announced Thursday that its Tagrisso (osimertinib) has been approved in the US for ...
Monthly Prescribing Reference5d
Tagrisso Approved for Stage III Unresectable EGFR-Mutated NSCLC
Results showed treatment with osimertinib reduced the risk of disease progression or death by 84% compared with placebo. The Food and Drug Administration (FDA) has approved Tagrisso ...
Business Wire5d
TAGRISSO ® (osimertinib) approved in the US for patients with unresectable, Stage III EGFR-mutated lung cancer
Patients were treated with TAGRISSO 80 mg once-daily oral tablets until disease progression, unacceptable toxicity or other discontinuation criteria were met. Upon progression, patients in the placebo ...
Nasdaq5d
AstraZeneca: FDA Approves Tagrisso To Treat Unresectable Stage III Lung Cancer
(RTTNews) - British drug major AstraZeneca PLC (AZN, AZN.L) announced Thursday that its Tagrisso (osimertinib) has been approved in the US for the treatment of adult patients with unresectable ...
Morningstar5d
TAGRISSO® (osimertinib) approved in the US for patients with unresectable, Stage III EGFR-mutated lung cancer
TAGRISSO(40 mg and 80 mg once-daily oral tablets) has been used to treat nearly 800,000 patients across its indications worldwide and AstraZeneca continues to explore TAGRISSOas a treatment for ...
Yahoo Finance4d
AstraZeneca’s Tagrisso gains FDA approval for stage III NSCLC
The US Food and Drug Administration (FDA) has approved AstraZeneca's Tagrisso (osimertinib) to treat adults with unresectable stage III EGFR-mutated non-small cell lung cancer (NSCLC).